Transcriptional Regulation of Metabolic and Hepatic Homeostasis by FoxO Signaling

FoxO 信号传导对代谢和肝脏稳态的转录调节

基本信息

  • 批准号:
    8272104
  • 负责人:
  • 金额:
    $ 27.41万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-05-01 至 2017-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This proposal "Transcriptional Regulation of Metabolic and Hepatic Homeostasis by FoxO Signaling" addresses the fundamental mechanism of diabetes by studying fuel hormone's action in the liver. Elevated blood glucagon levels and defective insulin action in patients with type 2 diabetes are responsible for hyperglycemia, but the molecular mechanisms remain elusive. Glucagon and insulin reciprocally control metabolic and cellular homeostasis, in which the liver is a major organ that executes their cellular functions. In the fasting liver, glucagon stimulates gluconeogenesis, degrades macromolecules including glycogen, lipid, and protein, and promotes the autophagic pathway that regulates cellular organelle turnover. In the feeding liver, insulin reverses the catabolic metabolism of glucagon. The metabolic and cellular adaptation from fasting to feeding requires a tight control of gene transcription by opposing effects of the two hormones, and the failure of the adaptation causes hyperglycemia in diabetes. The forkhead transcription factor Foxo1 that regulates multiple biological processes is inhibited by insulin signaling. Insulin phosphorylates Foxo1 at Ser253 in mice or S256 in humans via PKB activation, and triggers Foxo1 nuclear export and cytoplasmic sequestration for ubiquitination. Conversely, glucagon promotes Foxo1 protein stability in the fasting liver or the liver of diabetes when insulin level is decreased or insulin resistance occurs. Foxo1 can mediate the effect of cyclic AMP, the second messenger of glucagon, on expression of gluconeogenic enzymes and autophagic genes, but the role of Foxo1 and its regulation by glucagon, particularly in concert with insulin resistance, in metabolic regulation and cellular function is completely unclear. In Aim 1, we will use Foxo1 liver-specific knockout mice and examine whether Foxo1 is a key mediator in glucagon signaling to regulate hepatic glucose production, glycogenolysis, lipid and protein homeostasis, mitochondrial turnover and function, autophagy and survival, whereas disruption of Foxo1 prevents the glucagon-induced biological processes that promote the development of diabetes. In Aim2, we will use mass-spectrometry and phospho-specific antibodies to determine whether Foxo1 phosphorylation at S153 by glucagon and protein kinase PKA promotes nuclear targeting and whether phosphorylation at S276 enhances transcriptional activity in cells. In Aim 3, we have generated Foxo1- S253A mutant mice mimicking insulin resistance at the Foxo1 level in vivo. Using this unique mouse model, we will determine whether glucagon stimulates the effect of dephosphorylated Foxo1, disrupting metabolic and cellular homeostasis and liver function. In overall, we use Foxo1 gene loss- and gain-of-function approaches to investigate the physiological role of Foxo1 in glucagon action and identify novel molecular mechanisms of Foxo1 activation, which will advance our understanding of the mechanism of diabetes and help develop strategies detecting and inhibiting the glucagon->Foxo1 pathway to control the disease. PUBLIC HEALTH RELEVANCE: This project addresses the fundamental mechanisms of type 2 diabetes mellitus, in which excess glucagon and defective insulin action co-exist and promote metabolic and cellular dysfunction in the liver. Activation of Foxo1 protein by excess glucagon and insulin resistance coordinately plays a central role in controlling hepatic glucose, lipid, protein and amino acid metabolism, regulating liver function and failure in diabetes. Targeting the novel mechanism of Foxo1 activation in glucagon action can provide new strategies developing therapeutic intervention for the treatment of diabetes.
描述(由申请人提供):该提案“通过FoxO信号传导对代谢和肝脏稳态的转录调节”通过研究肝脏中燃料激素的作用来解决糖尿病的基本机制。2型糖尿病患者血胰高血糖素水平升高和胰岛素作用缺陷是导致高血糖症的原因,但其分子机制仍不清楚。胰高血糖素和胰岛素β控制代谢和细胞稳态,其中肝脏是执行其细胞功能的主要器官。在禁食肝脏中,胰高血糖素刺激肝脏新生,降解包括糖原、脂质和蛋白质在内的大分子,并促进调节细胞器更新的自噬途径。在进食肝脏中,胰岛素逆转胰高血糖素的分解代谢。从禁食到进食的代谢和细胞适应需要通过两种激素的相反作用来严格控制基因转录,并且适应的失败导致糖尿病中的高血糖症。 调节多种生物过程的叉头转录因子Foxo 1被胰岛素信号抑制。胰岛素通过PKB激活使Foxo 1在小鼠的Ser 253或人类的S256处磷酸化,并触发Foxo 1核输出和细胞质螯合以进行泛素化。相反,当胰岛素水平降低或发生胰岛素抵抗时,胰高血糖素促进空腹肝脏或糖尿病肝脏中Foxo 1蛋白的稳定性。Foxo 1可以介导胰高血糖素的第二信使环AMP对血管生成酶和自噬基因表达的影响,但Foxo 1及其受胰高血糖素调节的作用,特别是与胰岛素抵抗相关的作用,在代谢中的作用, 调节和细胞功能完全不清楚。在目标1中,我们将使用Foxo 1肝脏特异性敲除小鼠,并检查Foxo 1是否是胰高血糖素信号传导的关键介质,以调节肝脏葡萄糖产生,糖原分解,脂质和蛋白质稳态,线粒体周转和功能,自噬和存活,而Foxo 1的破坏阻止胰高血糖素诱导的生物过程,促进糖尿病的发展。在Aim 2中,我们将使用质谱和磷酸化特异性抗体来确定胰高血糖素和蛋白激酶PKA在S153处的Foxo 1磷酸化是否促进核靶向,以及S276处的磷酸化是否增强细胞中的转录活性。在目标3中,我们已经产生了Foxo 1-S253 A突变小鼠,在体内模拟Foxo 1水平的胰岛素抵抗。使用这种独特的小鼠模型,我们将确定胰高血糖素是否刺激去磷酸化Foxo 1的作用,破坏代谢和细胞稳态以及肝功能。总的来说,我们使用Foxo 1基因功能丧失和获得方法来研究Foxo 1在胰高血糖素作用中的生理作用,并确定Foxo 1激活的新分子机制,这将促进我们对糖尿病机制的理解,并有助于开发检测和抑制胰高血糖素-> Foxo 1通路以控制疾病的策略。 公共卫生相关性:该项目探讨了2型糖尿病的基本机制,其中过量的胰高血糖素和有缺陷的胰岛素作用共存,并促进肝脏的代谢和细胞功能障碍。过量胰高血糖素和胰岛素抵抗共同激活Foxo 1蛋白,在控制肝脏糖、脂、蛋白质和氨基酸代谢,调节肝功能和糖尿病衰竭中发挥重要作用。靶向胰高血糖素作用中Foxo 1激活的新机制可以提供开发用于治疗糖尿病的治疗干预的新策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Shaodong Guo其他文献

Research on the Comprehensive Benefit Evaluation of Electric Vehicle Technology Promotion and Application Under the Strategic Background of “Carbon Peaking and Carbon Neutrality”
  • DOI:
    10.1007/s42835-023-01643-4
  • 发表时间:
    2023-09-14
  • 期刊:
  • 影响因子:
    1.600
  • 作者:
    Dexiang Jia;Xinda Li;Shaodong Guo;Fang Liu;Chengcheng Fu;Xingde Huang;Zhen Dong;Jing Liu
  • 通讯作者:
    Jing Liu

Shaodong Guo的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Shaodong Guo', 18)}}的其他基金

Hepatic TGFbeta1 in Control of Type 2 Diabetes and NASH via FoxO1 Signaling
肝脏 TGFbeta1 通过 FoxO1 信号传导控制 2 型糖尿病和 NASH
  • 批准号:
    10532783
  • 财政年份:
    2021
  • 资助金额:
    $ 27.41万
  • 项目类别:
Hepatic TGFbeta1 in Control of Type 2 Diabetes and NASH via FoxO1 Signaling
肝脏 TGFbeta1 通过 FoxO1 信号传导控制 2 型糖尿病和 NASH
  • 批准号:
    10365367
  • 财政年份:
    2021
  • 资助金额:
    $ 27.41万
  • 项目类别:
Targeting Insulin Resistance by Estrogen Receptor in Control of Type 2 Diabetes Mellitus
通过雌激素受体靶向胰岛素抵抗来控制 2 型糖尿病
  • 批准号:
    10018033
  • 财政年份:
    2019
  • 资助金额:
    $ 27.41万
  • 项目类别:
Targeting Insulin Resistance by Estrogen Receptor in Control of Type 2 Diabetes Mellitus
通过雌激素受体靶向胰岛素抵抗来控制 2 型糖尿病
  • 批准号:
    10407999
  • 财政年份:
    2019
  • 资助金额:
    $ 27.41万
  • 项目类别:
Transcriptional Regulation of Metabolic and Hepatic Homeostasis by FoxO Signaling
FoxO 信号传导对代谢和肝脏稳态的转录调节
  • 批准号:
    8661768
  • 财政年份:
    2012
  • 资助金额:
    $ 27.41万
  • 项目类别:
Transcriptional Regulation of Metabolic and Hepatic Homeostasis by FoxO Signaling
FoxO 信号传导对代谢和肝脏稳态的转录调节
  • 批准号:
    8463523
  • 财政年份:
    2012
  • 资助金额:
    $ 27.41万
  • 项目类别:
Transcriptional Regulation of Metabolic and Hepatic Homeostasis by FoxO Signaling
FoxO 信号传导对代谢和肝脏稳态的转录调节
  • 批准号:
    9061672
  • 财政年份:
    2012
  • 资助金额:
    $ 27.41万
  • 项目类别:
Transcriptional Regulation of Metabolic and Hepatic Homeostasis by FoxO Signaling
FoxO 信号传导对代谢和肝脏稳态的转录调节
  • 批准号:
    9264906
  • 财政年份:
    2012
  • 资助金额:
    $ 27.41万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 27.41万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.41万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 27.41万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.41万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 27.41万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 27.41万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.41万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 27.41万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 27.41万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.41万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了